Nasdaq nmra.

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...Complete Neumora Therapeutics Inc. stock information by Barron's. View real-time NMRA stock price and news, along with industry-best analysis.THIRD QUARTER 2023 FINANCIAL RESULTS. The Company reported a net loss of $53.0 million for the third quarter of 2023, as compared to $29.3 million for the same period in 2022. Research and ...

Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update. The company’s shares trade on the Nasdaq under the stock symbol “NMRA.” Neumora is a new-ish company, having emerged with a $400 million Series A round of financing in 2021 after its initial formation in 2019. But the company’s history goes back further. Neumora represents the combination of five acquisitions, each bringing drug ...Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to NASDAQ Composite Index Sep. 18: CI Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. ... (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist in Phase 3 development as a potential monotherapy treatment for …

Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%.Explore Neumora Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 46 news, and 3 literature, Disease Domain ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...$8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...

View Neumora Therapeutics, Inc NMRA investment & stock information. Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The initiation of this Phase 1 study is an important step in the development of NMRA-266.Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ... The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Wednesday, November 8, 2023. The analyst firm set a price target ...Neumora Therapeutics Inc (NMRA). NASDAQ. Create Alert. Create Alert. New! Create Alert. Website. As an alert notification; To use this feature, make sure you ...

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Neumora Therapeutics (NASDAQ:NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with an ...Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …Obtenha uma breve visão geral das finanças de NEUMORA THERAPEUTICS INC com todos os números importantes. Veja o último NMRA demonstração de resultados, …Minim, Inc. (NASDAQ: MINM) gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday. ... (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics ...Nov 29, 2023 · markets.businessinsider.com - November 27 at 10:19 AM. Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. finance.yahoo.com - November 27 at 10:19 AM. Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $11.69. americanbankingnews.com - November 24 at 5:19 AM.

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.Victor J. Blue/Bloomberg. Shares of Watertown biotech Neumora Therapeutics retreated 4.4 percent Friday, in the company’s debut on the Nasdaq stock exchange, after it raised $250 million in an ...

Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .Uncover the latest insider trading activity for Neumora Therapeutics, Inc. (NMRA). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Neumora Therapeutics, Inc. NasdaqGS:NMRA Stock Report. Mkt Cap: US$1.8b.According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.Aug 28, 2023 · AzmanJaka. A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration ... NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.

According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.

15 Sep 2023 ... ... Nasdaq under the NMRA ticker, which could give it a market valuation of $2.74 billion if fully exercised. It is also due to make its debut ...

No Data Available. Neumora Therapeutics Inc. Annual stock financials by MarketWatch. View the latest NMRA financial statements, income statements and …Amneal Pharmaceuticals Stock (NYSE: AMRX) stock price, news, charts, stock research, profile.Insiders and Institutions Are Buying These Robot Stocks. This page (NASDAQ:NMRA) was last updated on 11/24/2023 by MarketBeat.com Staff. Adding. Choose a ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Nov 24, 2023 · A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...Sep 29, 2023 · Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ... Sep 21, 2023 · Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ... Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...Oct 10, 2023 · Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange.. RBC Capital Markets On Neumora Therapeutics ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...Instagram:https://instagram. apple traielrsamazon shares price historycasamigos ownervital energy stock Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. stock price for gildcan i get a heloc after refinancing NMRA Profile. Company Profile. Neumora Therapeutics Inc. 490 Arsenal Way. Suite 200. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. chargepoint share price NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...Sep 15, 2023 · Canopy Growth Corporation Common Shares. $1.165 -0.175 -13.06%. NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting ...